TRIPS

all 4 articles

If the proposals are agreed, they could delay the market entry of generic medicines in the region – and the impact will be felt around the world. Jeng_Niamwhan

RCEP: the trade agreement you’ve never heard of but should be concerned about

Seven rounds of negotiations for the Regional Comprehensive Economic Partnership have already taken place with virtually no public debate. The next round of negotiations begins today in Kyoto, Japan.
Pharmaceutical companies view the growing middle class in India and other emerging economies as a significant source of revenue. Ryan/Flickr

David and Goliath: Novartis challenges India’s patent law

India is the global focal point for legal and political struggles over patent rights and access to medicines. Particular attention is focused on the Swiss pharmaceutical giant Novartis, which is in battle…
Drug prices reduce dramatically when large multinationals’ monopoly is broken. m.p.3./Flickr

Big Pharma in legal battles for monopoly prices in India

Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s…
A Greens/EFA MEPs protest against ACTA at the European Parliament in Strasbourg. The protestors urged their fellow members to join them in standing up for democracy and a free internet. ©Photo European Union

Opening Pandora’s box: secret treaty threatens human rights

The Anti-Counterfeiting Trade Agreement (ACTA) 2011 - Twitter hashtag #ACTA - is a controversial trade agreement designed to provide for stronger enforcement of intellectual property rights. There’s been…

Top contributors

More